

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUA MEDICINE

華領醫藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2552)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO APPOINTMENT OF EXECUTIVE DIRECTOR

Reference is made to the announcement of Hua Medicine (the “**Company**”) dated December 29, 2023 (the “**Announcement**”) in relation to the appointment of Dr. Yi ZHANG (“**Dr. Zhang**”) as an executive Director with effect from January 1, 2024. Unless the context otherwise requires, capitalized terms used herein have the same meanings as those defined in the Announcement.

The Board would like to provide the following supplemental information of Dr. Zhang pursuant to Rule 13.51(2)(f) of the Listing Rules:

As at the date of the Announcement, Dr. Zhang was interested or deemed to be interested in, and as at the date of this announcement remains interested or deemed to be interested in, 11,633,320 shares of the Company (the “**Shares**”) within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), representing approximately 1.10% of the issued share capital of the Company as at the date of the Announcement and as at the date of this announcement, including (i) her holding of 1,500,000 Shares, and (ii) her entitlements to receive up to 10,133,320 Shares pursuant to the exercise of 9,733,320 share options granted to her under the pre-IPO share incentive scheme adopted by the Company on March 25, 2013 and pursuant to the exercise of 1,900,000 share options granted to her under the post-IPO share option scheme adopted by the Company on August 26, 2018.

Dr. Zhang confirmed to the Company that save as disclosed in this announcement, there is no other information in relation to her appointment which is required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules and there are no other matters in relation to her appointment that need to be brought to the attention of the shareholders of the Company.

Save as disclosed above, all other information disclosed in the Announcement remains unchanged.

By Order of the Board
Dr. Li Chen
Chief Executive Officer and Executive Director

Hong Kong, March 15, 2024

As of the date of this announcement, the Board comprises Dr. Li Chen, Mr. George Chien Cheng Lin and Dr. Yi Zhang as executive Directors; Mr. Robert Taylor Nelsen and Dr. Fangxin Li as non-executive Directors; and Mr. William Robert Keller, Mr. Yiu Wa Alec Tsui and Mr. Yiu Leung Andy Cheung as independent non-executive Directors.